L'Oréal

The board, chaired by Jean-Paul Agon, sets strategic direction with majority voting power resting in Tethys SAS, which holds the family's stake. Day-to-day capital allocation is managed by group CFO Christophe Babule and the M&A team for brand acquisitions, while L'Oréal Ventures operates under chief digital officer Asmita Dubey for early-stage deals. The dual Bettencourt-Meyers / Nestlé structure means any event requiring a supermajority vote must clear both blockholders (per the firm's annual report, 2023).

Yes. Tethys SAS functions as the Bettencourt Meyers family office, holding the group's controlling stake and managing family wealth separately from the operating company's balance sheet. The family office is distinct from L'Oréal's corporate venture arm, with Tethys focused on preserving the controlling block and making independent private investments, while L'Oréal Ventures deploys from the corporate P&L into beauty-adjacent technology startups.

The venture arm sources through partnerships with Station F in Paris and a California presence that taps the personal care innovation ecosystem in Los Angeles. The group also operates a direct R&D network of 21 research centers worldwide, creating an internal origination pipeline for clinical dermocosmetic assets. Brand acquisitions such as Aēsop and Skinbetter Science emerge from a specialized M&A team that evaluates independent prestige labels with gross margins above 65% (per Bloomberg, 2023).

Nestlé held approximately 23% of L'Oréal shares as a strategic blockholder for decades, the result of a 1974 agreement with Liliane Bettencourt that prevented either party from increasing its stake during her lifetime. In 2021, L'Oréal bought back roughly 4% from Nestlé for €8.2B, reducing the Swiss food giant's holding to approximately 20% and partially financed by selling Galderma to EQT. The relationship remains governed by a shareholder pact limiting transfers and granting reciprocal rights of first refusal.

The group avoids non-beauty adjacencies such as food, beverage, and household cleaning categories that its blockholder Nestlé occupies. Within personal care, L'Oréal has historically stayed away from heavily regulated prescription pharmaceutical development, instead focusing on cosmeceutical lines through La Roche-Posay and CeraVe that sit at the dermatology-beauty boundary without requiring full pharma clinical trials.

The Fondation L'Oréal operates as a legally independent entity with a separate budget governed by its own board. It runs the For Women in Science program through UNESCO and a humanitarian fund for women, while the L'Oréal Fund for Nature Regeneration is a €50M impact vehicle managed outside the corporate venture arm. Neither foundation holds equity in operating company assets, ensuring philanthropic allocations cannot be redeployed to commercial ends.

The corporate venture arm typically invests directly from the balance sheet rather than committing as an LP to external funds. When participating in rounds — such as the French biotech startup Debut — L'Oréal co-invests alongside traditional VCs like BOLD Capital Partners but structures the position as a direct corporate minority stake, which allows for technology-access rights and development agreements that a standard fund LP commitment would not provide.